MOSHE GARTY, M.D.; PAUL SOOD, Ph.D.; DOUGLAS E. ROLLINS, M.D., Ph.D.
Elevated serum digoxin concentrations and clinicial toxicity have been reported in patients receiving quinidine. The present study was undertaken to ascertain whether a similar interaction occurs between quinidine and another cardiac glycoside, digitoxin, and if so to evaluate the pharmacokinetic basis in five healthy volunteers. In the presence of quinidine the serum digitoxin concentration was elevated, the mean digitoxin elimination half-life was increased from 87.8 ± 11.6 to 218.3 ± 20.6 h (mean ± SEM) (p < 0.01), and mean total body clearance was reduced from 5.01 ± 1.18 to 1.87 ± 0.20 mL/h · kg (p < 0.052). No change was observed in the apparent volume of distribution or in the volume of the central compartment for digitoxin. The data suggest that the mechanism for this interaction is a reduction in elimination and not displacement of digitoxin from tissue binding sites.
MOSHE GARTY, PAUL SOOD, DOUGLAS E. ROLLINS. Digitoxin Elimination Reduced During Quinidine Therapy. Ann Intern Med. 1981;94:35–37. doi: 10.7326/0003-4819-94-1-35
Download citation file:
Published: Ann Intern Med. 1981;94(1):35-37.
Cardiology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use